Royalty Pharma buys partial royalty interest on Prevymis from AiCuris Anti-infective Cures GmbH
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.
Pharmaceuticals, Biotechnology and Life Sciences
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.
Packaging Technology Group, Inc., (PTG), a leading provider of thermal packaging solutions for the biopharmaceutical and life sciences sector, has opened a new location in Louisville, Kentucky.
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is the world’s leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed…
TORONTO–(BUSINESS WIRE)–#FSDDF—FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private…
In the absence of ‘in person’ meetings, access to deep dive pharma insights are not on hold, and later this month experts will discuss how AI is rapidly evolving supply chain dynamics in a ground-breaking Pharmapack Europe webinar (June 17, 2020).
RECARBRIO is Indicated to Treat Multiple Infections Caused by Susceptible Gram-Negative Bacteria in Adults KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…
New fund will be deployed to create breakthrough biotech startups Michael Gladstone is promoted to partner CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atlas Venture,…
Mylan and Lupin Limited have received from the European Commission (EC) marketing authorization for Nepexto, a biosimilar to Enbrel, for all indications of the reference product.
The first weed control traits in rice and flax bred by precision gene editing to be advanced in commercial development…
New subcutaneous, fixed-dose formulation of daratumumab reduces treatment time from hours to minutes, with comparable efficacy and fewer infusion-related reactions1,2…